CN111184748A - Microbial agent for improving muscular atrophy and application thereof - Google Patents
Microbial agent for improving muscular atrophy and application thereof Download PDFInfo
- Publication number
- CN111184748A CN111184748A CN202010084509.4A CN202010084509A CN111184748A CN 111184748 A CN111184748 A CN 111184748A CN 202010084509 A CN202010084509 A CN 202010084509A CN 111184748 A CN111184748 A CN 111184748A
- Authority
- CN
- China
- Prior art keywords
- muscle
- veillonella
- ruminococcus
- muscle atrophy
- microbial agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000585 muscular atrophy Diseases 0.000 title claims abstract description 44
- 230000000813 microbial effect Effects 0.000 title claims abstract description 22
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 36
- 241001148134 Veillonella Species 0.000 claims abstract description 33
- 230000020763 muscle atrophy Effects 0.000 claims abstract description 32
- 241000192031 Ruminococcus Species 0.000 claims abstract description 30
- 210000003205 muscle Anatomy 0.000 claims abstract description 28
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 5
- 239000002054 inoculum Substances 0.000 claims 5
- 241000305071 Enterobacterales Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 24
- 230000006872 improvement Effects 0.000 abstract description 21
- 241000894006 Bacteria Species 0.000 abstract description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 235000021120 animal protein Nutrition 0.000 description 6
- 238000010219 correlation analysis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241001478240 Coccus Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000004767 rumen Anatomy 0.000 description 5
- 241000606125 Bacteroides Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000588748 Klebsiella Species 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 3
- 241001057811 Paracoccus <mealybug> Species 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241000589565 Flavobacterium Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 241000605947 Roseburia Species 0.000 description 2
- 241001608455 Rossia <Bacillariophyta> Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 235000021196 dietary intervention Nutrition 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940071440 soy protein isolate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000025161 regulation of muscle atrophy Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a microbial agent for improving muscle atrophy and application thereof, and relates to the technical field of intestinal bacteria application. The microbial agent comprises intestinal bacteria, wherein the intestinal bacteria comprise Ruminococcus (Ruminococcus) and/or veillonella (veillonella), and the Ruminococcus (Ruminococcus) and/or veillonella (veillonella) in the intestinal tract, and both the two bacteria can improve the symptoms of muscle atrophy, increase the muscle area and improve the muscle grasping force, show obvious positive correlation with the improvement of the muscle atrophy and can be used for improving the symptoms of the muscle atrophy.
Description
Technical Field
The invention belongs to the technical field of intestinal bacteria application, and particularly relates to a microbial agent for improving muscular atrophy and application thereof.
Background
Skeletal muscle accounts for about 40% of body weight and plays a vital role in maintaining human health, including amino acid and glucose metabolism, protein storage and exercise. Muscle atrophy is a chronic metabolic disease commonly faced by people in modern society, and people lack of exercise for a long time, old people, cancer patients and people treated by large dose of hormones face different degrees of muscle atrophy. Studies have shown that muscle atrophy has become an independent factor affecting death. Therefore, how to effectively improve muscle atrophy has become a health problem to be solved urgently.
The previous research is mainly to research the mechanism of muscle atrophy from the perspective of cell signaling pathways. Unfortunately, it has not been possible to screen for drugs that either block the cell signaling pathways associated with regulation of muscle atrophy, or that do not produce new side effects. Therefore, new ways for improvement are urgently sought. Since the human intestinal flora is a complex ecosystem, it can influence the absorption of nutrients by biotransformation of food complexes, while their metabolites can enter the blood circulation through the intestinal tight junctions and enter the muscle tissue. These research clues suggest that intestinal flora may be an effective target for regulating muscle atrophy. However, no research is currently available to find strains of gut microbes that can ameliorate muscle atrophy.
Disclosure of Invention
In view of the above, the present invention aims to provide a microbial agent for improving muscular atrophy and an application thereof, so that intestinal flora can be used as an effective target for regulating muscular atrophy, the symptom of muscular atrophy is improved, the muscle area is improved, and the muscle grasping force is improved.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a microbial agent for improving muscle atrophy, which comprises intestinal bacteria, wherein the intestinal bacteria comprise rumen coccus (Ruminococcus) and/or veillonella (veillonella).
The invention also provides a nutritional supplement for improving muscle atrophy, which comprises the microbial agent.
The invention also provides the application of the microbial agent or the nutritional supplement in preparing a nutrient for improving muscle area.
The invention also provides application of the microbial agent or the nutritional supplement in preparing a nutritional product for improving muscle grip.
The invention provides a microbial agent for improving muscle atrophy, which comprises Ruminococcus (Ruminococcus) and/or veillonella (veillonella) in intestinal bacteria. The intestinal bacteria are obtained by screening the excrement of a hematopoietic stem cell transplantation patient with long-term muscle atrophy by a clinical queuing method; then, the abundance value of the intestinal probiotics is correlated with the corresponding muscle atrophy improvement degree, and the correlation coefficient of the Ruminococcus (Ruminococcus) with the muscle area improvement is 0.65(p is 0.2), and the correlation coefficient of the Ruminococcus (Ruminococcus) with the muscle grasping force is 0.78(p is 0.06); the correlation coefficient of veillonella (veillonella) with the improvement of muscle area is up to 0.75(p is 0.08), and the correlation coefficient with the muscle grip is 0.55(p is 0.25). Therefore, the rumen coccus (Ruminococcus) and veillonella (veillonella) show obvious positive correlation with improvement of muscle atrophy and can be used for improving the symptoms of the muscle atrophy.
Drawings
FIG. 1 is a graph showing the correlation analysis between Ruminococcus (Ruminococcus) and the improvement of muscle area;
FIG. 2 is a graph showing the correlation analysis between Ruminococcus (Ruminococcus) and muscle grip;
FIG. 3 is a graph of correlation analysis of Veillonella (veillonella) with muscle area improvement;
FIG. 4 is a graph of correlation analysis of Veillonella (veillonella) with muscle grip;
fig. 5 is a flow chart of the screening of the intestinal probiotics.
Detailed Description
The invention provides a microbial agent for improving muscle atrophy, which comprises intestinal bacteria, wherein the intestinal bacteria comprise rumen coccus (Ruminococcus) and/or veillonella (veillonella).
The source of the Ruminococcus (Ruminococcus) and/or veillonella (veillonella) is not limited at all, and the Ruminococcus and/or veillonella may be purchased from conventional commercial strains (strains) or extracted from intestinal tract or intestinal tract excreta. In the present example, to explain the effect of the enteric bacteria, it is preferable to screen intestinal excreta of a hematopoietic stem cell transplant patient with long-term muscle wasting according to the procedure shown in fig. 5. The present invention preferably further comprises prior to said screening, performing a two month quality protein nutritional intervention on said patient, said intervention preferably comprising caloric intake of 35kcal/kg/d, protein intake of 1.5 g/kg/d; the protein comprises animal protein and plant protein, and the mass ratio of the animal protein to the plant protein is 1: 1. The animal protein of the present invention preferably comprises a soy protein isolate, preferably purchased from the prince royal group (cat No. YP928H, shandong, china). The animal protein according to the present invention preferably comprises whey protein, preferably purchased from Livingston (hilmr 9410, Livingston, CA, USA). According to the invention, the patients after the dry prognosis are preferably judged to have the muscle atrophy improvement effect through muscle CT scanning, and are divided into two groups (the muscle atrophy improvement population and the non-improvement population) according to the quality of the muscle improvement effect, and the intestinal microorganism specimens of the two groups of populations before and after protein intervention are subjected to 16srDNA sequencing respectively. After the sequencing, the sequence set is divided into operable classification units (OTUs) by using UCLUST under a 97% consistency threshold, and each OTU is classified and distributed by similarity through a GLSEARCH program; then using Metastats analysis (analysis of significant difference between groups), which improves the population by comparing muscle atrophy and does not improve the intestinal strains of the first 20% abundance of intestinal flora in the population, the strains with significant statistical differences, i.e., Enterococcus (Enterococcus), Veillonella (Veillonella), Ruminococcus (Ruminococcus), Bacteroides (Bacteroides), Klebsiella (Klebsiella), flavobacterium (flavonifibracter), clostridium (Fusobacterium), paracoccus (paracoccular), Streptococcus (strepococcus) and rossia (Roseburia), were found by the analysis of difference between groups; finally, the differential bacteria are subjected to correlation analysis according to the abundance value and the corresponding muscle atrophy improvement degree, and the rumen coccus (Ruminococcus) and veillonella (veillonella) are found to show obvious positive correlation with the muscle atrophy improvement.
The invention also provides a nutritional supplement for improving muscle atrophy, which comprises the microbial agent. The nutritional supplement of the present invention can provide nutritional intervention to improve muscle wasting in patients, thereby promoting increased muscle area and increased muscle grip.
The invention also provides the application of the microbial agent or the nutritional supplement in preparing a nutrient for improving muscle area. The nutritional product of the present invention preferably further comprises conventional food grade adjuvants.
The invention also provides application of the microbial agent or the nutritional supplement in preparing a nutritional product for improving muscle grip. The application of the present invention is preferably the same as described above and will not be described further herein.
The microbial agents for improving muscle atrophy and the applications thereof provided by the present invention will be described in detail with reference to the following examples, but they should not be construed as limiting the scope of the present invention.
Example 1
The protocol of this example was carried out using the method of clinical Cohort (Cohort study). The embodiment of the invention is registered by a Chinese clinical registration center (ChiCTR 1800017765).
Screening was performed according to the scheme shown in FIG. 5: by recruiting hematopoietic stem cell transplant patients with long-term muscular atrophy and by performing a two month long-term intervention with high quality protein nutrition (35 kcal/kg/d caloric intake, 1.5g/kg/d protein intake; wherein the protein consists of animal protein and vegetable protein in a 1:1 mass ratio, wherein the vegetable protein is soy protein isolate (YP928H, royal Livingston, Shandong, China) and the animal protein is whey protein (Hilmar9410, Livingston, CA, USA)) on all cohorts. The muscle atrophy improvement effect was judged by muscle CT scan two months later. Then, dividing the group into two groups according to the quality of the muscle improvement effect (the muscle CT scanning and the holding power value after the intervention of the patient, calculating the difference value of the CT muscle area change and the holding power change before and after the intervention, listing the group with positive difference values of the two indexes as a muscle improvement group, listing the group with negative difference values of the two indexes as a muscle atrophy non-improvement group), and respectively carrying out 16srDNA sequencing on the intestinal microorganism samples before and after the protein intervention of the two groups of people.
The intestinal flora 16srDNA analysis method comprises the following steps:
DNA was extracted from the thawed fecal samples. DNA quality was determined by 2% agarose gel electrophoresis and spectrophotometry. The V3-V4 region of the 16srDNA gene was amplified with Fastpfu DNA polymerase (TransStartTM, TransGen Biotech).
The primer adopted is 336F (SEQ ID NO. 1): 5'-GTACTCCTAGGGGGCAGCA-3', respectively;
806R(SEQ ID NO.2)：5'-GTGGACTACHVGGGTWTCTAAT-3'。
the PCR cycling conditions were as follows: pre-denaturation at 95 ℃ for 5 min; denaturation at 85 ℃ for 45s, annealing at 55 ℃ for 50s, extension at 72 ℃ for 45s, 28 cycles; prolonging the temperature at 72 ℃ for 10 min.
The purified amplicons were pooled in equimolar amounts and paired-end sequencing was performed according to standard protocols on the Illumina MiSeq platform (2 × 300). The sequence set is divided into actionable taxons at a consistency threshold of 97% using UCLUST (otu). Using the GLSEARCH program, each OTU was assigned by similarity, yielding a total of 1311239 high quality sequences with coverage over 99%. The OTU representative sequences are analyzed by alignment using RDP Classifier algorithm (default) or blast, uclust consensus xonomy assigner and the like, and species information of the colonies is annotated at various levels (kingdom, phylum, compendium, family, genus and species).
Methods for the study of improvement of Ruminococcus (Ruminococcus) and veillonella (veillonella) and muscle atrophy:
metastats analysis, i.e., analysis of significant differences between groups, was used. This analysis improved the population by comparison to muscle wasting and did not improve the intestinal strain of pre-abundance 1/5 intestinal flora in the population, and found strains with significant statistical differences by analysis of differences between groups, i.e. enterococci (Enterococcus), Veillonella (Veillonella), Ruminococcus (Ruminococcus), Bacteroides (Bacteroides), Klebsiella (Klebsiella), flavobacterium (flavonocarpactor), clostridia (Fusobacterium), paracoccus (paracoccus), Streptococcus (stretococcus) and rossia (Roseburia); finally, the differential bacteria are subjected to correlation analysis according to the abundance value and the corresponding muscle atrophy improvement degree (the results are shown in figures 1 to 4), and the rumen coccus (Ruminococcus) and veillonella (veillonella) are found to show obvious positive correlation with the muscle atrophy improvement.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> research institute for food and nutrition development in rural area of agriculture
<120> microbial agent for improving muscular atrophy and application thereof
<160>2
<170>SIPOSequenceListing 1.0
<210>1
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
gtactcctag ggggcagca 19
<210>2
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
gtggactach vgggtwtcta at 22
Claims (4)
1. A microbial inoculant for improving muscle atrophy, wherein the microbial inoculant comprises enterobacteria, and the enterobacteria comprise Ruminococcus (Ruminococcus) and/or Veillonella (Veillonella).
2. A nutritional supplement for ameliorating muscle wasting comprising the microbial inoculant of claim 1.
3. Use of the microbial inoculant of claim 1 or the nutritional supplement of claim 2 in the preparation of a nutritional product for improving muscle area.
4. Use of the microbial inoculant of claim 1 or the nutritional supplement of claim 2 in the manufacture of a nutritional product for improving muscle grip.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010084509.4A CN111184748A (en) | 2020-02-10 | 2020-02-10 | Microbial agent for improving muscular atrophy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010084509.4A CN111184748A (en) | 2020-02-10 | 2020-02-10 | Microbial agent for improving muscular atrophy and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111184748A true CN111184748A (en) | 2020-05-22 |
Family
ID=70686159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010084509.4A Pending CN111184748A (en) | 2020-02-10 | 2020-02-10 | Microbial agent for improving muscular atrophy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111184748A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US20180255821A1 (en) * | 2017-03-10 | 2018-09-13 | International Nutrition Research Company | Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases |
| CN109310715A (en) * | 2016-04-11 | 2019-02-05 | 哈佛学院董事及会员团体 | For promoting the probiotics preparation of athletic performance |
-
2020
- 2020-02-10 CN CN202010084509.4A patent/CN111184748A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| CN109310715A (en) * | 2016-04-11 | 2019-02-05 | 哈佛学院董事及会员团体 | For promoting the probiotics preparation of athletic performance |
| US20180255821A1 (en) * | 2017-03-10 | 2018-09-13 | International Nutrition Research Company | Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases |
Non-Patent Citations (3)
| Title |
|---|
| 夏亚丽: "益生菌对老年人健康促进作用的机制研究进展", 《中国营养学会第十四届全国营养科学大会暨第十一届亚太临床营养大会》 * |
| 焦金真 等: "浏阳黑山羊胃肠道不同部位重要功能微生物的数量分布特征研究 ", 《畜牧兽医学报》 * |
| 高键，葛声主编: "《吃对就健康》", 31 January 2010, 上海科学技术文献出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Intestinal microbiota of gibel carp (Carassius auratus gibelio) and its origin as revealed by 454 pyrosequencing | |
| Janczyk et al. | Microbial community composition of the crop and ceca contents of laying hens fed diets supplemented with Chlorella vulgaris | |
| Hammons et al. | A small variation in diet influences the Lactobacillus strain composition in the crop of broiler chickens | |
| Matsui et al. | Microbial diversity in ostrich ceca as revealed by 16S ribosomal RNA gene clone library and detection of novel Fibrobacter species | |
| CN102549162B (en) | Strains and methods for improving ruminant health and/or performance | |
| De Cesare et al. | Effect of a low protein diet on chicken ceca microbiome and productive performances | |
| US11951138B2 (en) | Microbial compositions comprising rumen microflora and uses thereof | |
| CN102823772B (en) | Porcine heat stress resistance selenium-rich composite bacteria feed additive and application thereof | |
| CN1272877A (en) | Feed product | |
| CN1739027A (en) | Predicting animal performance | |
| Mao et al. | Use of pyrosequencing to characterize the microbiota in the ileum of goats fed with increasing proportion of dietary grain | |
| CN108522884B (en) | Application of composite microecological preparation in preventing fat deposition of broiler chickens | |
| CN109266576A (en) | A kind of enterococcus faecalis and its application method | |
| Zhu et al. | Comparative study of the bacterial communities throughout the gastrointestinal tract in two beef cattle breeds | |
| Hong et al. | Bacterial diversity at different sites of the digestive tract of weaned piglets fed liquid diets | |
| Guo et al. | Enhanced intestinal microflora composition and phosphorus-transportation efficiency in fast-growing spotted seabass (Lateolabrax maculatus) fed a low-phosphorus diet | |
| Wang et al. | Comparative analysis of the intestinal microbiota in goldfish and crucian carps between different aquaponics and traditional farming | |
| CN111184748A (en) | Microbial agent for improving muscular atrophy and application thereof | |
| CN115820458B (en) | Bifidobacterium longum 050101 with ulcerative colitis relieving effect and application thereof | |
| Enoka et al. | Effect of garlic and onion extract chitosan nanoparticles on selected intestinal bacterial flora in indigenous rainbow rooster chicken in Kenya. | |
| CN111117935A (en) | Microbial agent for inhibiting muscle synthesis and application thereof | |
| Wang et al. | Fermentation profile and microbial diversity of temperate grass silage inoculated with epiphytic microbiota from tropical grasses | |
| CN114786494A (en) | Microbiome intervention | |
| Gagnon et al. | Evaluation of bacterial diversity in the gut of piglets supplemented with probiotics using ribosomal intergenic spacer analysis | |
| KR102169139B1 (en) | Compostion for improving intestinal microflora of poultry comprising Allium hookeri powder as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200522 |
|
| RJ01 | Rejection of invention patent application after publication |